miR‑145‑5p is associated with pathological complete response to neoadjuvant chemotherapy and impairs cell proliferation by targeting TGFβR2 in breast cancer

• DOI: 10.3892/or.2019.7102
• Publication Date: 2019-04-05T12:35:15Z
• Authors: Frederik Garc�a‑G...; Yarely Salinas‑Vera; Ra�l Garc�a‑V�zquez; Laurence Marchat; Sergio Rodr�guez‑...; Jos� L�pez‑Gonz�lez; �ngeles Carlos‑Reyes; Rosal�o Ramos‑Pay�n; Maribel Aguilar‑M...; Carlos P�rez‑Plas...; Erika Ru�z‑Garc�a; C�sar L�pez‑Camar...
• Keywords: Neoadjuvant Therapy; Ectopic expression; Triple-negative breast cancer

Cancer patients who better benefit from neoadjuvant chemotherapy (NeoCh) are those achieve a successful pathological complete response (pCR) represented by the absence of residual disease. Unfortunately, no highly sensitive and specific tumor biomarkers for predicting clinical to NeoCh have yet been defined. The aim present study was ascertain whether miR‑145‑5p could discriminate between pCR no‑pCR in triple‑negative breast cancer that received cisplatin/doxorubicin‑based treatment. expression determined tumors quantitative RT‑PCR. Our data showed had significant low (P<0.005) achieved comparison non‑responder group. Kaplan Meier analysis indicated levels were associated with increased disease‑free survival. In addition, receiver operating characteristic (ROC) curve suggested is good predictor (P<0.003, AUC=0.7899, 95% CI, 0.6382‑0.9416). Quantitative RT‑PCR also revealed downregulated four cell lines relative normal cells. To functions miR‑145‑5p, its restored MDA‑MB‑231 cells effects proliferation evaluated MTT assays apoptosis using Annexin V experiments. Data ectopic resulted inhibition induced apoptosis. Moreover, led sensitization cisplatin therapy. western blot TGFβR2 protein. conclusion, be potential biomarker cancer. Functionally may regulate proliferation, at least part, targeting TGFβR2.